Artal Group’s Adverum Biotechnologies ADVM Stock Holding History

Artal Group’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300,000	Closed	-$3.6M	–	136
2022 Q2	$3.6M	Hold	300,000	–	–	0.19%	75
2022 Q1	$3.93M	Hold	300,000	–	–	0.16%	91
2021 Q4	$5.28M	Hold	300,000	–	–	0.14%	100
2021 Q3	$6.51M	Hold	300,000	–	–	0.15%	102
2021 Q2	$10.5M	Buy	300,000 +60,000	+25%	+$3.23M	0.21%	86
2021 Q1	$23.7M	Sell	240,000 -10,000	-4%	-$1.2M	0.42%	54
2020 Q4	$27.1M	Buy	250,000 +70,000	+39%	+$8.66M	0.58%	45
2020 Q3	$18.5M	Buy	180,000 +90,000	+100%	+$13.5M	0.45%	49
2020 Q2	$18.8M	Buy	90,000 +30,000	+50%	+$5.31M	0.53%	44
2020 Q1	$5.86M	Buy	+60,000	New	+$7M	0.25%	70
2018 Q4	–	Sell	-40,000	Closed	-$2.42M	–	105
2018 Q3	$2.42M	Hold	40,000	–	–	0.06%	95
2018 Q2	$2.12M	Hold	40,000	–	–	0.05%	93
2018 Q1	$2.32M	Buy	+40,000	New	+$2.49M	0.03%	91
2015 Q2	–	Sell	-10,000	Closed	-$4.05M	–	71
2015 Q1	$4.05M	Buy	+10,000	New	+$4.23M	0.19%	62

Other funds holding ADVM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SFI

Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Artal Group's ADVM Position: Q3 2022 in Review

Artal Group sold out of Adverum Biotechnologies (ADVM) in Q3 2022, closing a stake of 300,000 shares — an estimated $3.6M sold.

Artal Group first reported a position in ADVM in Q1 2015 and held it in 14 quarters. The position peaked at $27.1M in Q4 2020. 78 funds tracked by Wall St. Rank hold ADVM as of Q3 2022.

Artal Group reported no remaining Adverum Biotechnologies position as of Q3 2022 after selling out during the quarter.
Artal Group sold 300,000 Adverum Biotechnologies shares in Q3 2022, an estimated $3.6M.
Artal Group first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 14 quarters.
Artal Group's Adverum Biotechnologies position peaked at $27.1M in Q4 2020.
78 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2022.

Based on Artal Group's 13F filing for Q3 2022, filed 14 Nov 2022.